Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics

In a trial combining Keytruda with Oncologie’s investigational drug that targets phosphatidylserine, the response rate was 43% among patients with a low neutrophil-to-lymphocyte ratio.